MDxHealth SA completed a registered direct Placement of 44,052,862 ordinary shares for $20 million at $0.454 per share. The company reported $19.2 million in cash and says it can fund operations for at least twelve months, while warning that continued losses create substantial doubt about its ability to continue as a going concern.

Key Highlights

  • Revenue reached $51.106 million for the six months ended June 30, 2026.
  • Financial expenses were $8.766 million during the period.
  • Nasdaq notified MDxHealth SA that its shares had traded below the $1.00 minimum bid price for 30 consecutive Business days.

MDxHealth SA (NASDAQ: MDXH) completed a registered direct placement that generated $20 million in gross proceeds. The company says it has sufficient cash to continue operating for at least the next twelve months, but a material uncertainty casts substantial doubt on its ability to remain a going concern.

$20M Placement Completed

The placement involved 44,052,862 ordinary shares, or 44.1 million shares, sold at $0.454 per Ordinary Share. The company expects continued losses and negative operating cash flows during the coming twelve months.

Interim Losses Continue

Revenue for the six months ended June 30, 2026, was $51.106 million, while Gross Profit reached $32.559 million. Selling and Marketing expenses were $22.804 million, general and administrative expenses were $16.235 million, and Research and Development expenses were $4.129 million. The operating loss was $13.263 million. Financial income was $2.855 million against financial expenses of $8.766 million, producing a loss before income tax of $19.174 million. Loss from continuing operations was $19.174 million, while discontinued operations contributed a loss of $1.225 million net of tax. Total basic and diluted loss per share was $0.40, comprising $0.37 from continuing operations and $0.03 from discontinued operations.

Cash and Nasdaq Requirements

Cash and cash equivalents stood at $19.2 million as of June 30, 2026. MDxHealth SA says its forecasts support the view that available cash can fund operations for at least twelve months from the date the financial statements were issued, provided it can maintain adequate cash levels and access additional financing. Nasdaq also notified the company that its ordinary shares were below the $1.00 minimum bid price requirement for 30 consecutive business days. The first written notice was received on June 30, 2026, based on closing bid prices from May 15 through June 29, 2026. A further written notice was received on July 20, 2026, regarding continued non-compliance with the requirement. Failure to meet Nasdaq Capital Market continued-listing requirements could result in delisting of the company’s securities.